Replies to post #23664 on Intellipharmaceutics International Inc. (IPCI)

[Samsa]

Angelo......I was always pretty close with what you came up with. I had estimated a while back that the generics alone should generate around 40 million a year. so pretty close!

I agree with your other post, that with Focalin fully commercialized and Seroquel, we should be cash positive by 3QE and possibly profitable by 4QE17.

the fact Seroquel is a cost plus agreement we know there is profit built in. so regardless of the royalties we are going to make a profit on manufacturing we just don't know how much.

then just imagine if the FDA approves just 1 more ANDA that is already partnered with MNK?

[Amigo Mike]

Angelo,

Love your projections but 20% royalty on a generic drug ..... I don't think is reasonable to use.

Bottomline generic royalties are much lower. You said yourself you came up with 10% royalty on focalin during the exclusivity period and lower thereafter. So I'm not certain how you are starting at 20%. The high end royalties are only in play when there is licensing of groundbreaking IP involved. In the generic space of the ANDA candidates, there is no groundbreaking differentiator for IPCI IMO.

Amigo Mike